PRKAG2

Across TCGA pan-cancer cohorts, PRKAG2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRKAG2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PRKAG2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRKAG2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where PRKAG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	1.000	0.317	.001	17	view →
PDAC	DFS	Median	III,IV	0.475	0.214	.012	13	view →
CCRCC	OS	Median	III,IV	0.819	1.000	.019	8	view →
UCEC	DFS	Median	II,III,IV	0.870	0.545	.043	8	view →
HNSC	OS	Quartile	II,III,IV	0.925	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRKAG2–LSCC (DFS)

Open the LSCC breakdown →